FILE PHOTO: The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg, France, February 1, 2018. Picture taken February 1, 2018. REUTERS/Vincent Kessler

Home » News » World News » Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say

World News

Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say

by ReutersJune 17, 2025

(Reuters) -Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday.

Verve is developing therapies targeting genes that regulate cholesterol in the liver.

Join the discussion → Share your thoughts!

Read more from our local writers → Candidate for Clay Twp Supervisor - Tony Brasfield

(Reporting by Sriparna Roy in Bengaluru; Editing by Pooja Desai)

New York Giants' Theo Johnson named potential breakout player to watch

Reuters

Information you can trust. Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers. (c) 2025 Thomson Reuters

Candidate for Clay Twp Supervisor – Tony Brasfield

Candidate for State Senate – Randy Schulz

Candidate for Michigan Supreme Court – Judge Michael Warren

MSU Board Crisis – Michael Balow

Fetal Alcohol Syndrome – Jim Casha

CSCB – Michael McCarten

Candidate for St Clair County Commissioner – Kelly Tucker

Temujin Kensu 40 Years – Joy Marie Mann

Rise & Shine! It is Liberty Time! – Paul Urben

The Danger of Birchwood Mall – Stephanie Seaman

Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say

Reuters

Leave a Comment Cancel Reply

Related posts

Leave a Comment Cancel Reply